TIL therapy

Oncology An experimental CA therapy in which antigen-
specific tumor-infiltrating T lymphocytes–TILs are isolated from biopsies of Pts with CA and co-administered with IL-2. Cf LAK/IL-2 therapy.

Mentioned in ?

therapy

References in periodicals archive ?

These early data from the head and neck study show the potential safety and efficacy of TIL therapy in tumor types other than melanoma, and demonstrate the broad utility of TIL therapy in various solid tumors.

Iovance announces preliminary Phase 2 data for TIL treatment

TIL therapy is being evaluated in physician-sponsored clinical trials at MD Anderson Cancer Center and Moffitt Cancer Center.

Lion Biotechnologies submits Investigational New Drug Application with US FDA for cervical, head and neck cancer

In this role, he was instrumental in driving the company s metastatic melanoma TIL program into clinical development in the first TIL therapy trial performed outside an academic center.

Germany : Merck Appoints Laszlo Radvanyi as Head of Global Immuno-Oncology Research

The impetus for the current experiment grew out of Rosenberg's previous experience with TIL therapy as reported last year in the Dec.

TIL therapy aims at bolstering a patient's own immune response to cancer.

Gene-transfer trial begins in humans

Cntego[TM] is based on the TIL therapy developed by Dr.

Genesis Biopharma Receives FDA Meeting Minutes from Cntego[TM] Pre-IND Meeting

TIL therapy is also being evaluated in physician-sponsored clinical trials at MD Anderson Cancer Center and Moffitt Cancer Center.

Lion Biotechnologies awarded US FDA's orphan drug status for LN-144 for malignant melanoma

Having exclusivity meaningfully de-risks our development and commercialisation efforts, putting us in an even stronger position to investigate TIL therapy in the treatment of metastatic melanoma.

Lion Biotechnologies receives license for patents to develop tumour-infiltrating lymphocytes therapy

CITE

Site: Follow: Share:

Open / Close